These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29718970)

  • 1. The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.
    Peng H; Chen L; Chen YP; Li WF; Tang LL; Lin AH; Sun Y; Ma J
    PLoS One; 2018; 13(5):e0196730. PubMed ID: 29718970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
    Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
    Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
    Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
    Jiang WH; Zhao SP; Yin ZH; Li F; Chen ZH; Xiao JY
    Ai Zheng; 2005 Jul; 24(7):796-800. PubMed ID: 16004803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
    An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
    Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.
    Nakanishi Y; Wakisaka N; Kondo S; Endo K; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Yoshizaki T
    Cancer Metastasis Rev; 2017 Sep; 36(3):435-447. PubMed ID: 28819752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
    Zhang Y; Gao HY; Feng HX; Deng L; Huang MY; Hu B; Cheng G; Wu QL; Cui NJ; Shao JY
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):982-6. PubMed ID: 15312530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
    Chan KC; Hung EC; Woo JK; Chan PK; Leung SF; Lai FP; Cheng AS; Yeung SW; Chan YW; Tsui TK; Kwok JS; King AD; Chan AT; van Hasselt AC; Lo YM
    Cancer; 2013 May; 119(10):1838-44. PubMed ID: 23436393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma.
    Tan EL; Selvaratnam G; Kananathan R; Sam CK
    BMC Cancer; 2006 Sep; 6():227. PubMed ID: 16995954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
    Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma.
    Chen CL; Sheen TS; Lou IU; Huang AC
    Hum Pathol; 2001 Nov; 32(11):1240-4. PubMed ID: 11727264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.